Screener
Cytek Biosciences, Inc. CTKB Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Legal settlement liability, noncurrent | 6,368 | 6,786 |
| Deferred revenue, noncurrent | 18,058 | 18,339 |
| Operating lease liability, noncurrent | 13,517 | 14,042 |
| Long-term debt | 246 | 525 |
| Other noncurrent liabilities | 2,456 | 2,307 |
| Total liabilities | 124,980 | 119,803 |
| Commitments and contingencies (Note 17) | ||
| Stockholders’ equity: |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s long-term debt?
- Cytek Biosciences, Inc. (CTKB) reported long-term debt of $246K in Q2 2026.
- How has Cytek Biosciences, Inc.'s long-term debt changed year-over-year?
- Cytek Biosciences, Inc.'s long-term debt decreased by 68.9% year-over-year, from $791K to $246K.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Cytek Biosciences, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude